Reprint
Metabolism and Metabolomics of Liver in Health and Disease
Edited by
February 2021
268 pages
- ISBN978-3-03943-635-4 (Hardback)
- ISBN978-3-03943-636-1 (PDF)
This book is a reprint of the Special Issue Metabolism and Metabolomics of Liver in Health and Disease that was published in
Biology & Life Sciences
Summary
Women and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; Fibrosis; Liver biopsy; Genomics; Metabolomics; Proteomics; Transcriptomics; nicotinamide; NAFLD; steatosis; heat stress; primary mouse hepatocytes; metabolic profile; GC-MS; multivariate statistical analysis; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; arachidonic acid; docosahexaenoic acid; inflammation; fibrosis; lipidomics; mass spectrometry; in vitro; HepaRG; sodium saccharin; reference toxicants; de novo lipogenesis; carbohydrate response element-binding protein; ChREBP; diabetes; glucose production; glycogen; glycolysis; glycogen storage disease type I; hexosamine; nonalcoholic fatty liver disease; NAFLD; pentose phosphate pathway; steatosis; nonalcoholic fatty liver disease; acupuncture; imflammation; lipid metabolism; oxidative stress; metabolomics quantitative profiling; lipidomics; 1H-NMR spectroscopy; liver; steatosis; bile acids; metabolomics; rat plasma; tandem mass spectrometry; liquid chromatography; acetaminophen; hepatotoxicity; metabolomics; lipidomics; biomarker; premalignant; alcoholic liver disease; cholestasis; fibrosis; cirrhosis; NAFL; NASH; metabolomics; standard operating procedures; urine; blood; feces; tissue; cells; liver function; nonalcoholic fatty liver; nonalcoholic steatohepatitis; liquid chromatography-mass spectrometry; nuclear magnetic resonance spectroscopy; metabolic pathway; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; transcription factors; inflammation; metabolic stress; fibrosis; lipid homeostasis; glucose homeostasis